

Ref. No: 0201
Date: 18/08/23
Subject: Treatment of Dermatological Conditions

REQUEST

1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:
 - Abrocitinib
 - Acitretin
 - Alitretinoin
 - Azathioprine
 - Baricitinib
 - Ciclosporin
 - Dupilumab
 - Methotrexate
 - Mycophenolate mofetil
 - Pimecrolimus
 - Phototherapy (UVB or PUVA)
 - Tacrolimus ointment
 - Tralokinumab
 - Upadacitinib
2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?
3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:
 - a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?
 - b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib?
 - c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
 - d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretinoin, Pimecrolimus or Tacrolimus?

RESPONSE

1) How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:

- Abrocitinib **0**
- Acitretin **156**
- Alitretinoin **6**
- Azathioprine **29**
- Baricitinib **6**
- Ciclosporin **53**
- Dupilumab **81**
- Methotrexate **391**
- Mycophenolate mofetil **14**
- Pimecrolimus **88**
- Phototherapy (UVB or PUVA) **no record in pharmacy**
- Tacrolimus ointment **152**
- Tralokinumab **0**
- Upadacitinib **<5**

**Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

2) How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?

81

3) For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:

a) How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?

74

b) How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies –

Abrocitinib, 0
Baricitinib, <5
Tralokinumab 0
and Upadacitinib? 0

**Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

c) How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants –

Methotrexate, <5

**Ciclosporin, 0
Mycophenolate <5
or Azathioprine? 0**

**Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.

d) How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following –

**Acitretin, 0
Alitretoin 0
Pimecrolimus <5
or Tacrolimus? <5**

**Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.